Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
Xu, J., Wei, L., Mathvink, R.J., Edmondson, S.D., Eiermann, G.J., He, H., Leone, J.F., Leiting, B., Lyons, K.A., Marsilio, F., Patel, R.A., Patel, S.B., Petrov, A., Scapin, G., Wu, J.K., Thornberry, N.A., Weber, A.E.(2006) Bioorg Med Chem Lett 16: 5373-5377
- PubMed: 16919457 
- DOI: https://doi.org/10.1016/j.bmcl.2006.07.061
- Primary Citation of Related Structures:  
2HHA - PubMed Abstract: 
A novel series of oxadiazole based amides have been shown to be potent DPP-4 inhibitors. The optimized compound 43 exhibited excellent selectivity over a variety of DPP-4 homologs.
Organizational Affiliation: 
Department of Medicinal Chemistry, Merck & Co., Inc., PO Box 2000, Rahway, NJ 07065, USA. Jinyou_Xu@merck.com